Robert C. Kane
Impact in
- Hematology top 2%
- Multiple Myeloma Research and Treatments
- Oncology top 2%
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
Papers in
-
- Multiple Myeloma Research and Treatments 3
- Erythropoietin and Anemia Treatment 3
- Chronic Myeloid Leukemia Treatments 3
- Iron Metabolism and Disorders 3
- Genetics 5
- Chronic Lymphocytic Leukemia Research 3
- Co-authors
- Richard PazdurAnn T. FarrellRajeshwari SridharaPeter BrossRobert JusticeChia‐Wen KoBrian BoothRamzi Dagher
- Journals
- Clinical Cancer Research (6 papers)The Oncologist (5 papers)JAMA (2 papers)International Journal of Radiation Oncology*Biology*Physics (1 paper)Blood (1 paper)
- Partner nations
- United StatesItalyIndia
In The Last Decade
Robert C. Kane
31 papers receiving 3.0k citations
Hit Papers
Peers
Comparison fields: 5 of 128
- Hematology 628
- Oncology 1.1k
- Genetics 282
- Molecular Biology 1.4k
- Hepatology 155
Countries citing papers authored by Robert C. Kane
This map shows the geographic impact of Robert C. Kane's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert C. Kane with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert C. Kane more than expected).
Fields of papers citing papers by Robert C. Kane
This network shows the impact of papers produced by Robert C. Kane. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert C. Kane. The network helps show where Robert C. Kane may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Robert C. Kane, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 131 | |
| 2 | 2016 | 27 | |
| 3 | 2016 | 25 | |
| 4 | 2015 | 261 | |
| 5 | 2015 | 151 | |
| 6 | 2014 | 32 | |
| 7 | 2013 | 23 | |
| 8 | 2012 | 19 | |
| 9 | 2009 | 187 | |
| 10 | 2008 | 58 | |
| 11 | 2007 | 276 | |
| 12 | 2006 | 281 | |
| 13 | 2003 | 16 | |
| 14 | 2003 | 8 | |
| 15 | 1980 | 37 | |
| 16 | 1979 | 73 | |
| 17 | Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma. | 1979 | 19 |
| 18 | 1978 | 1 | |
| 19 | Adriamycin therapy in American patients with hepatocellular carcinoma. | 1977 | 40 |
| 20 | 1976 | 44 |
About Robert C. Kane
Robert C. Kane is a scholar working on Hematology, Genetics, Anesthesiology and Pain Medicine, Speech and Hearing and Oncology, having authored 32 papers that have together received 3.0k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (3 papers), Multiple Myeloma Research and Treatments (3 papers), Erythropoietin and Anemia Treatment (3 papers), Health Systems, Economic Evaluations, Quality of Life (3 papers), Chronic Myeloid Leukemia Treatments (3 papers), Iron Metabolism and Disorders (3 papers), Protein Degradation and Inhibitors (3 papers) and Pain Management and Opioid Use (2 papers). The work is most often cited by research in Hematology (628 citations), Oncology (1.1k citations), Genetics (282 citations), Molecular Biology (1.4k citations) and Hepatology (155 citations). Robert C. Kane has collaborated with scholars based in United States, Italy and India. Frequent co-authors include Richard Pazdur, Ann T. Farrell, Rajeshwari Sridhara, Peter Bross, Robert Justice, Chia‐Wen Ko, Brian Booth, Ramzi Dagher, Haleh Saber and Shenghui Tang. Their work appears in journals such as Clinical Cancer Research, The Oncologist, JAMA, International Journal of Radiation Oncology*Biology*Physics and Blood.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.